Citi analyst Yigal Nochomovitz lowered the firm’s price target on Ardelyx (ARDX) to $10 from $12 and keeps a Buy rating on the shares. Despite the uncertainty around Xphozah’s longer-term commercial path, Ardelyx “delivered another exceptional quarter” with Xphozah’ sales of $51.5M, above the consensus of $46M, demonstrating robust demand even in the early innings of the launch, the analyst tells investors in a research note. Citi believes Xphozah “remains a compelling growth story.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARDX:
- Ardelyx price target raised to $13.50 from $12.50 at Ladenburg
- Ardelyx Reports Robust Q3 2024 Revenue Growth
- Ardelyx reports Q3 EPS 0c, consensus (5c)
- Ardelyx options imply 14.6% move in share price post-earnings
- ARDX Earnings this Week: How Will it Perform?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
